ABSTRACT
Introduction Little is known about the relation of cognitive impairment (CI) to COVID-19 mortality. Here, we analyse the frequency of CI in deceased COVID-19 patients.
Methods We included 477 adult cases that died after admission from March 1 to March 31, 2020: 281 with confirmed COVID-19, 58 probable COVID-19, and 138 who died of other causes.
Results The number of comorbidities was high in the confirmed COVID-19, and CI was common (30%: 21.1% dementia; 8.9% mild cognitive impairment). Subjects with CI were older, more lived in nursing homes and had shorter times from symptom onset to death than those without CI. COVID-19 patients with CI were rarely admitted to the ICU and fewer received non-invasive mechanical ventilation, but palliative care was provided more often.
Conclusions Dementia is a frequent comorbidity in COVID-19 deceased patients. The burden of COVID-19 in the dementia community will be high.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Dr. Victor Blanco-Palmero is supported by the Instituto de Salud Carlos III (ISCIII; Spanish Biomedical Research Institute) thorough a Rio Hortega contract (CM 18/00095). Dr. Sara Llamas-Velasco is supported by the Instituto de Salud Carlos III (ISCIII; Spanish Biomedical Research Institute) thorough a Juan Rodes contract (JR 18/00046).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was reviewed and approved by the local ethics committee / institutional review board (EC/IRB).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
DISCLOSURE OF CONFLICT OF INTEREST. The authors declare no financial or other conflicts of interest.
FUNDING. Dr. Victor Blanco-Palmero is supported by the Instituto de Salud Carlos III (ISCIII; Spanish Biomedical Research Institute) thorough a “Río Hortega” contract (CM 18/00095).
Dr. Sara Llamas-Velasco is supported by the Instituto de Salud Carlos III (ISCIII; Spanish Biomedical Research Institute) thorough a “Juan Rodés” contract (JR 18/00046).
Data Availability
Anonymized data may be available upon reasonable request from qualified researchers.
